Evidence map›Paper›PMID 35371104›Full record

ArticleFrontiers in immunology2022

Chronic Alcohol Exposure Among People Living with HIV Is Associated with Innate Immune Activation and Alterations in Monocyte Phenotype and Plasma Cytokine Profile.

Michelle L Underwood, Byung Park, Luke S Uebelhoer, Geoffrey Gu, Lynn E Kunkel, Philip T Korthuis, Ryan R Cook, Rafick Pierre Sekaly, Susan Pereira Ribeiro, Christina L Lancioni

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Michelle L UnderwoodDepartment of Pediatrics, Oregon Health & Science University, Portland, OR, United States.
Byung ParkKnight-Cancer Institute, Department of Biostatistics, Oregon Health & Science University, Portland, OR, United States.
Luke S UebelhoerDepartment of Pediatrics, Oregon Health & Science University, Portland, OR, United States.
Geoffrey GuUndergraduate Studies, University of Southern California, Los Angeles, CA, United States.
Lynn E KunkelDepartment of Medicine, Oregon Health & Science University, Portland, OR, United States.
Philip T KorthuisDepartment of Medicine, Oregon Health & Science University, Portland, OR, United States.
Ryan R CookDepartment of Medicine, Oregon Health & Science University, Portland, OR, United States.
Rafick Pierre SekalyDepartment of Pathology & Translational Medicine, Emory University School of Medicine, Atlanta, GA, United States.
Susan Pereira RibeiroDepartment of Pathology & Translational Medicine, Emory University School of Medicine, Atlanta, GA, United States.
Christina L LancioniDepartment of Pediatrics, Oregon Health & Science University, Portland, OR, United States.
Oregon Health & Science University · USEmory University · USUniversity of Southern California · US

Funding

The Ohio Valley Node of the Clinical Trials Network (CTN-0153)UG1DA013732 · NIDA · UNIVERSITY OF CINCINNATI · PI T John WINHUSEN · 2015 to 2026
$42.5M
Western States Node of the National Drug Abuse Treatment Clinical Trials Network (TMS for CUD) UG1DA015815 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Keith N. Humphreys, Philip Todd Korthuis · 2015 to 2026
$24.6M
The impact of naltrexone treatment on opioid-induced immune and viral dysregulation during HIV-infectionR01DA046229 · NIDA · OREGON HEALTH & SCIENCE UNIVERSITY · PI LANCIONI, CHRISTINA LOUISE · 2018 to 2022
$3.1M
Immune dysregulation in HIV-infected adults with substance abuse and the impact of addiction therapyR03DA039731 · NIDA · OREGON HEALTH & SCIENCE UNIVERSITY · PI LANCIONI, CHRISTINA LOUISE · 2016 to 2017
$308k
NIDA NIH HHS R01 DA046229NIDA NIH HHS R03 DA039731NIDA NIH HHS UG1 DA013732NIDA NIH HHS UG1 DA015815
6 · The paper itself

Abstract

Despite advances in antiretroviral therapy, chronic immune activation continues to be observed among individuals with well-controlled HIV viral loads, and is associated with non-AIDS defining morbidities among people living with HIV. Alcohol use disorder impacts a significant proportion of individuals living with HIV, and alcohol exposure is known to damage the intestinal epithelium which may increase translocation of pathogens and their molecular products, driving systemic immune activation and dysregulation. The aim of this study was to determine if adults living with HIV with well-controlled viral loads, who also suffer from alcohol use disorder with and without hepatitis C virus co-infection (n=23), exhibit evidence of advanced systemic immune activation, intestinal damage, and microbial translocation, as compared to adults living with HIV who are not exposed to chronic alcohol or other substances of abuse (n=29). The impact of a 1-month intervention to treat alcohol-use disorder was also examined. Alcohol-use disorder was associated with evidence of advanced innate immune activation, alterations in monocyte phenotype including increased expression of Toll-like receptor 4, increased burden of stimulatory ligands for Toll-like receptor 4, and alterations in plasma cytokine signature, most notably elevations in soluble CD40 ligand and transforming growth factor beta. Alcohol-associated immune activation was more pronounced among individuals with hepatitis C virus co-infection. Although the 1-month intervention to treat alcohol use disorder did not result in significant reductions in the interrogated indicators of immune activation, our findings suggest that chronic alcohol exposure is a major modifiable risk factor for chronic immune activation and dysregulation among people-living with HIV.

Indexed as

AlcoholismCoinfectionHepatitis CHIV InfectionsCytokinesHepacivirusHumansImmunity, InnateMonocytesPhenotypeToll-Like Receptor 4CytokinesToll-Like Receptor 4alcohol-use-disorderhepatitis Chuman immuno deficiency virus (HIV)inflammationinnate immunity

Identifiers

PMID35371104
PMCPMC8971672
OpenAlexW4220804620

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.